A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Second Generation Antipsychotics in Subjects With Stable Schizophrenia | C4C

Schizophrenia is a chronic, debilitating psychiatric condition that affects up to 1% of people throughout the world and places a substantial burden on patients, their families, and society. To date there are no approved medications addressing negative symptoms or cognitive impairment associated with schizophrenia. Negative symptoms (social withdrawal, loss of emotional responsivity, lack of engagement with everyday activities) can include social withdrawal, decreased motivation, impaired communication, lack of pleasure in things once found pleasurable. This study will investigate the treatment of negative symptoms of schizophrenia with a novel medication (TAK-041).